Serum biomarkers as signals for risk and severity of work-related musculoskeletal injury

Biomarkers in Medicine

Volumn 2, Issue 1, 2008, Pages 67-79

  Carp, Stephen J ^a   Barr, Ann E ^b   Barbe, Mary F ^a  

^a TEMPLE UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biomarkers; Collagen turnover; Inflammation; Repetitive strain injury; Work related musculoskeletal disorder

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CREATINE KINASE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANGIOGENESIS; ARM INJURY; CARPAL TUNNEL SYNDROME; CELL ACTIVATION; CELL ADHESION; CELL PROLIFERATION; CELL STRESS; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DISEASE ASSOCIATION; EXERCISE INTENSITY; HUMAN; HYPERTENSION; ILLNESS BEHAVIOR; INJURY SEVERITY; MUSCULOSKELETAL INJURY; NONHUMAN; OBESITY; OCCUPATIONAL ACCIDENT; OCCUPATIONAL HEALTH; OSTEOLYSIS; OVERTRAINING SYNDROME; PATHOGENESIS; PHAGOCYTE; REVIEW; RISK ASSESSMENT;

EID: 41249089942     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.1.67     Document Type: Review

References (62)

1. National Research Council and Institute of Medicine. Musculoskeletal Disorders and the Workplace: Low Back and Upper Extremities. National Academy Press, Washington, DC, USA (2001).
2. Barr AE. Systems approach to rehabilitation In: The Occupational Ergonomics Handbook: Interventions Controls and Applications in Occupational Ergonomics (2nd Edition). Marras WS, Karwowski W (Eds). CRC Taylor and Francis, Boca Raton, FL, USA 34-21 (2006).
3. Kumar S: Theories of musculoskeletal injury causation. Ergonomics 44(1), 17-47 (2001).
4. Barr AE, Barbe MF, Clark BD: Systemic inflammatory mediators contribute to widespread effects in work-related musculoskeletal disorders. Exercise Sport Sci. Rev. 32(4), 135-142 (2004).
5. Wu AH: Early detection of acute coronary syndromes and risk stratification by multimarker analysis. Biomarkers Med. 1(1), 45-57 (2007).
6. Lim W, Qushmaq I, Cook DJ, Crowther MA, Heels-Ansdell D, Devereaux PJ: Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. Crit. Care 9(6), 636-664 (2005).
7. Clayton M, Elkhettabi F, Khap FM et al.: Improved prediction of prostate cancer recurrence through systems pathology. J. Clin. Invest. 117, 1876-1883 (2007).
8. Abramavotz M, Leyland-Jones B: A systems approach to clinical oncology: focus on breast cancer. Proteome Sci. 4, 477-486 (2006).
9. Goldmann BU, Christenson RH, Hamm CW, Meinertz T Ohman EM: Implications of troponin testing in clinical medicine. Curr. Control. Trials Cardiovasc. Med. 2(2), 75-84 (2001).
10. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary artery heart diseases, is interleukin-6 the link? Atherosclerosis 48, 209-214 (2001).
11. Dinarrello CA: The IL-1 family and inflammatory diseases. Clin, Exp. Rheumatol. 5(Suppl. 27), S1-S13 (2002).
12. Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology 39, 237-246 (2002).
13. Jimi E, Aoki K, Saito H et al.: Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10(6), 617-624 (2004).
14. Dantzer R: Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 500(1-3), 399-411 (2004).
15. Feldmann M, Brennan FM, Williams RO: Evaluation of the role of role of cytokines in autoimmune disease: the importance of TNF-α in rheumatoid arthritis. Prog. Growth Factor Res. 4, 247-255 (1994).
16. Ruminy P, Gangneux C, Claeyssens S, Scott M, Daveau M, Salier JP: Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target organ. Inflamm. Res. 50, 383-390 (2001).
17. Ershler WB, Keller ET: Age associated increased Interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51, 245-270(2000).
18. Biffl WL, Moore EE, Moore FA, Peterson VM: Interleukin-6 in the injured patient: marker of injury or mediator of inflammation? Ann. Surg. 224, 647-664 (1996).
19. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83, 113-118 (1994).
20. Pedersen BK, Steensberg A, Fischer C et al. The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc. Nutr. Soc. 63, 263-267 (2004).
21. Ballou SP Kushner I: C-reactive protein and the acute phase response. Adv. Interm. Med. 37, 313-336 (1992).
22. Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am. J. Clin. Pathol. 116(Suppl.), S108-S115.
23. Liuzzo G, Biasucci LM, Gallimore JR et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engi. J. Med. 331(7), 417-424 (1994).
24. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R: Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28, 690-693, (2005).
25. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M: Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am. J. Cardiol. 96, 1374-1378 (2005).
26. Nijmeijer R, Lagrand WK, Visser CA, Meijer CJ, Niessen HW, Hack CE: CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int. Immunopharmacol. 1, 403-414 (2001).
27. Lagrand WK, Visser CA, Hermens WT et al.: C-reartive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100, 96-102 (1999).
28. Archambault JM, Jelinsky SA, Lake SP, Hill AA, Glaser DL, Soslowsky LJ: Rat supraspinatus tendon expresses cartillage markers with overuse. J. Orthop. Res. 25, 617-624 (2007).
29. Barbe MF, Barr AE, Gorzelany I, Amin M, Gaughan JP, Safadi FF: Chronic repetitive reaching and grasping results in decreased motor performance and widespread tissue responses in a rat model of MSD. J Orthop. Res. 21, 167-176 (2003).
30. Clark BD, Al-Shatti TA, Barr AE, Amin M, Barbe MF: Performance of a high-repetition, high-force task induces carpal tunnel syndrome in rats. J. Orthop. Sports Phys. Ther. 34, 244-253 (2004).
31. Clark BD, Barr AE, Safadi FF, Beitman L, Al-Shatti T, Barbe MF: Median nerve trauma in a rat model of work-related musculoskeletal disorder. J. Neurotrauma 20, 681-695 (2003).
32. Nakama LH, King KB, Abrahamsson S, Rempel DM: Effect of repetition rate on the formation of microtears in tendon in an in vivo cyclical loading model. J. Orthop. Res. 25(9), 1176-1184 (2007).
33. Sommerich CM, Lavender SA, Buford JA, Banks JJ, Korkmaz SV, Pease WS: Towards development of a nonhuman primate model of carpal tunnel syndrome: performance of a voluntary, repetitive pinching task induces median mononeuropathy in Maraca fascicularis. J. Orthop. Res. 25, 713-724 (2007).
34. Barr AE, Safadi FF, Gorzelany I, Amin M, Popoff SN, Barbe ME Repetitive, negligible force reaching in rats induces pathological overloading of upper extremity bones. J. Bone Miner. Res. 18, 2023-2032 (2003).
35. Perry SM, McIlhenny SE, Hoffman MC, Soslowsky LJ: Inflammatory and angiogenic mRNA levels are altered in a supraspinatus tendon overuse animal model. J. Shoulder Elbow Surg. 14, S79-S83 (2005).
36. Al-Shatti T, Barr AE, Safadi FF, Amin M, Barbe MF: Increase in inflammatory cytokines in median nerves in a rat model of repetitive motion injury. J. Neuroimmunol. 167(1-2), 13-22 (2005).
37. Carp SJ, Barbe MF, Winter KA, Amin M, Barr AE: Inflammatory biomarkers increase with severity of upper-extremity overuse disorders. Clin. Sci. 112, 305-314 (2007)
38. Kramer JF, Potter P, Harburn KL, Speechley M, Rollman GB: An upper body musculoskeletal assessment instrument for patients with work-related muscoloskeletal disorders: a pilot study. J. Hand Ther. 14, 115-121 (2001).
39. Freeland AE, Tucci MA, Barbieri RA, Angel MF, Nick TG: Biochemical evaluation of serum and flexor tenosynovium in carpal tunnel syndrome. Microsurgery 22, 378-385 (2002).
40. Haddy N, Sass C, Maumus S et al.: Biological variations, genetic polymorphisms and familial resemblance of the TNF-α and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet. 13, 109-117 (2005).
41. Macy EM, Hayes TE, Tracy R: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 43, 52-58 (1997).
42. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J: Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 15, 771-772 (1994).
43. Ridker PM, Cushman M, Stampfer MJ, Tracy RP. Hennekens CH: Inflammation aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997).
44. Chrysohoou C, Pitsavos C, Pangiotakos DB, Skouma J, Stefandis C: Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am. J. Hypertens. 17, 568-573 (2004).
45. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C: the implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 183, 308-315 (2005).
46. Svoboda P, Kantorova I, Ochmann J: Dynamics of interleukin 1, 2,.and 6 and tumor necrosis factor-α in multiple trauma patients. J. Trauma 36, 336-340 (1994).
47. Nieman DC, Henson DA, Davis JM et al.: Blood leukocyte mRNA expression for IL-10, IL-1 RA, and IL-8, but not IL-6, increases after exercise. J. Interferon Cytokine Res. 26, 668-674 (2006).
48. Ostrowski K, Rohde T, Asp S, Schjerling P, Klarland-Pedersen B: Pro- and anti-inflammatory cytokine balance in astrenuous exercise in humans. J. Physiol. 515, 287-291 (1999).
49. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Klarlund-Pedersen B: IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle. Am. J. Physiol. Metab. 283, E1272-E1278 (2002).
50. Smith LL, Anwar A, Fragen M, Rinanto C, Johnson R, Holert D: Cytokines and cell adhesion molecules associated with high-intensity eccentric exercise. Eur. J. Appl. Physiol. 82, 61-67 (2000).
51. Kim HJ, Lee HY, Kim CK: Biomarkers of muscle and cartilage damage and inflammation during a 200km run. Eur. J. Appl. Physiol. 99(4), 443-447 (2007).
52. Ezirmik N, Kiziltunc A, Keskin D, Yildirim AK, Karsan O, Saruhan O: Soluble intercellular adhesion molecule 1, tumor necrosis factor-α, and interleukin-6 levels after trauma. The Pain Clinic 15 (3), 235-240 (2003).
53. Bruunspard H, Galbo H, Halkjaer-Kristensen J, Johansen TL, MacLean DA, Pederson BK: Exercise-induced increase in serum IL-6 in humans related to muscle damage. J. Physiol. 499, 833-841 (1997).
54. Watkins LR, Wiertelak EP, Goehler LE et al.: Neurocircuitry of illness-induced hyperaigesia. Brain Res. 639, 283-289 (1994).
55. Bret-Dibat JL, Bluthe RM, Kent S, Kelly, Dantzer R: Lipopolysaccharide and interleukin- 1 depress food-motivating behavior in mice by a vagal-mediated mechanism. Brain Behav. Immun. 9, 242-246 (1995).
56. Clays E, De Bacquer D, Delanghe J, Kittel F, Van Renterghem L, De Backer G: Associations between dimensions of job stress and biomarkers of inflammation and infection. J Occup. Environ. Med. 47, 878-993 (2005).
57. Schaller S, Henriksen K, Hoegh-Andersen P et al.: In vitro, ex vivo, and in vivo methodological approaches fro studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev. Technol. 3(4), 553-580 (2005).
58. Kuiper JI, Van Dieen JH, Everts V, Verbeek JHAM, Frings-Dresen MHW: Associations between serum markers of collagen metabolism and spinal shrinkage. Clin. Biomech. (Bristol, Avon) 19, 209-212 (2004).
59. Kuiper JI, Verbeek JH, Everts V, Straub JP, Frings-Dresen MH: Serum markers of collagen metabolism: construction workers compared to sedentary workers. Occup. Environ. Med. 62(6), 363-367 (2005).
60. Kuiper JI, Verbeek JHAM, Straub MP, Everts V, Frings-Dresen MHW: Physical workload of student nurses and serum markers of collagen metabolism. Scand. J. Work Environ. Health 28(2), 168-175 (2002).
61. Suvanto-Luukkonen E, Ristell L, Sundstrom H, Penttinen J, Kauppila A, Risteli J: Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin. Chim. Acta 266, 105-116 (1997).
62. Rosenquist C, Fledelius C, Christgau S et al.: First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type 1 collagen. Clin. Chem. 44, 2281-2289 (1998).